Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15757502
Rolfe M, McLeod LE, Pratt PF, Proud CG (2005) Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 388, 973-84 15757502
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T35-p - 4E-BP1 (rat)
Modsite: LPPGDYsttPGGtLF SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T36‑p, 4E‑BP1 (mouse): T35‑p, 4E‑BP1 (rat): T35‑p, 4E‑BP1 (fruit fly): S36‑p, 4E‑BP1 (cow): T36‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 no change compared to control
SB203580 no change compared to control
CGP57380 no change compared to control
phenylephrine increase
U0126 phenylephrine no effect upon treatment-induced increase
SB203580 phenylephrine no effect upon treatment-induced increase
CGP57380 phenylephrine inhibit treatment-induced increase
rapamycin no change compared to control
rapamycin phenylephrine no effect upon treatment-induced increase

T44-p - 4E-BP1 (rat)
Modsite: PGGtLFSttPGGtRI SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T45‑p, 4E‑BP1 (mouse): T44‑p, 4E‑BP1 (rat): T44‑p, 4E‑BP1 (fruit fly): T45‑p, 4E‑BP1 (cow): T45‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 no change compared to control
SB203580 no change compared to control
CGP57380 no change compared to control
phenylephrine increase
U0126 phenylephrine no effect upon treatment-induced increase
SB203580 phenylephrine no effect upon treatment-induced increase
CGP57380 phenylephrine inhibit treatment-induced increase
rapamycin no change compared to control
rapamycin phenylephrine no effect upon treatment-induced increase

T308-p - Akt1 (rat)
Modsite: KDGATMKtFCGTPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine no change compared to control
insulin insulin DUSP6 (human) no effect upon treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) no change compared to control

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine increase
insulin insulin DUSP6 (human) inhibit treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  translation, altered
Comments:  phenylphrine induces protein synthesis

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine increase
insulin insulin DUSP6 (human) inhibit treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  translation, altered
Comments:  phenylphrine induces protein synthesis

T179-p - ERK2 (rat)
Modsite: ADPDHDHtGFLtEyV SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T181‑p, ERK2 (mouse): T179‑p, ERK2 (rat): T179‑p, ERK2 (chicken): T189‑p, ERK2 (cow): T181‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine increase
insulin insulin DUSP6 (human) inhibit treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  translation, altered
Comments:  phenylphrine induces protein synthesis

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine increase
insulin insulin DUSP6 (human) inhibit treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  translation, altered
Comments:  phenylphrine induces protein synthesis

S21-p - GSK3A (rat)
Modsite: SGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phenylephrine increase
U0126 phenylephrine inhibit treatment-induced increase
insulin increase
U0126 insulin no effect upon treatment-induced increase

S9-p - GSK3B (rat)
Modsite: SGRPRTTsFAESCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phenylephrine increase
U0126 phenylephrine inhibit treatment-induced increase
insulin increase
U0126 insulin no effect upon treatment-induced increase

T180-p - P38A (rat)
Modsite: RHTDDEMtGyVATRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine increase
insulin insulin DUSP6 (human) no effect upon treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) no effect upon treatment-induced increase

Y182-p - P38A (rat)
Modsite: TDDEMtGyVATRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phenylephrine increase
insulin insulin DUSP6 (human) no effect upon treatment-induced increase
phenylephrine phenylephrine DUSP6 (human) no effect upon treatment-induced increase

S939-p - TSC2 (rat)
Modsite: KFRARSTsLNERPKS SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): S939‑p, TSC2 iso2 (human): S939‑p, TSC2 iso3 (human): S939‑p, TSC2 iso4 (human): S939‑p, TSC2 (mouse): S939‑p, TSC2 iso6 (mouse): S939‑p, TSC2 (rat): S939‑p, TSC2 iso2 (rat): S939‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
LY294002 phorbol_ester no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
insulin increase WT tuberin
phorbol_ester increase WT tuberin
insulin no change compared to control S939/1466A mutant
phorbol_ester augment treatment-induced decrease S939/1466A mutant

T1466-p - TSC2 (rat)
Modsite: GLRPRGYtISDSAPS SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phenylephrine increase slight increase at 60 min
insulin increase
insulin increase
phorbol_ester increase
U0126 phorbol_ester inhibit treatment-induced increase
LY294002 phorbol_ester no effect upon treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
insulin increase WT tuberin
phorbol_ester increase WT tuberin
insulin no change compared to control S939/1466A mutant
phorbol_ester augment treatment-induced decrease S939/1466A mutant